FOLD
Price
$6.10
Change
+$0.15 (+2.52%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
1.88B
28 days until earnings call
IMUX
Price
$0.73
Change
+$0.02 (+2.82%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
68.1M
35 days until earnings call
Interact to see
Advertisement

FOLD vs IMUX

Header iconFOLD vs IMUX Comparison
Open Charts FOLD vs IMUXBanner chart's image
Amicus Therapeutics
Price$6.10
Change+$0.15 (+2.52%)
Volume$245.69K
Capitalization1.88B
Immunic
Price$0.73
Change+$0.02 (+2.82%)
Volume$5.58K
Capitalization68.1M
FOLD vs IMUX Comparison Chart in %
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. IMUX commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a StrongBuy and IMUX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (FOLD: $5.95 vs. IMUX: $0.71)
Brand notoriety: FOLD and IMUX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 76% vs. IMUX: 38%
Market capitalization -- FOLD: $1.88B vs. IMUX: $68.1M
FOLD [@Biotechnology] is valued at $1.88B. IMUX’s [@Biotechnology] market capitalization is $68.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileIMUX’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • IMUX’s FA Score: 0 green, 5 red.
According to our system of comparison, IMUX is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 5 TA indicator(s) are bullish while IMUX’s TA Score has 5 bullish TA indicator(s).

  • FOLD’s TA Score: 5 bullish, 2 bearish.
  • IMUX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than IMUX.

Price Growth

FOLD (@Biotechnology) experienced а +5.12% price change this week, while IMUX (@Biotechnology) price change was +1.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

IMUX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($1.88B) has a higher market cap than IMUX($68.1M). IMUX YTD gains are higher at: -28.930 vs. FOLD (-36.837). FOLD has higher annual earnings (EBITDA): 53.6M vs. IMUX (-100.85M). FOLD has more cash in the bank: 251M vs. IMUX (14.3M). IMUX has less debt than FOLD: IMUX (975K) vs FOLD (443M). FOLD has higher revenues than IMUX: FOLD (543M) vs IMUX (0).
FOLDIMUXFOLD / IMUX
Capitalization1.88B68.1M2,758%
EBITDA53.6M-100.85M-53%
Gain YTD-36.837-28.930127%
P/E RatioN/AN/A-
Revenue543M0-
Total Cash251M14.3M1,755%
Total Debt443M975K45,436%
FUNDAMENTALS RATINGS
FOLD vs IMUX: Fundamental Ratings
FOLD
IMUX
OUTLOOK RATING
1..100
1271
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
8765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUX's Valuation (49) in the Pharmaceuticals Major industry is in the same range as FOLD (64) in the Biotechnology industry. This means that IMUX’s stock grew similarly to FOLD’s over the last 12 months.

IMUX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as FOLD (100) in the Biotechnology industry. This means that IMUX’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (93) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that FOLD’s stock grew similarly to IMUX’s over the last 12 months.

IMUX's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as FOLD (87) in the Biotechnology industry. This means that IMUX’s stock grew similarly to FOLD’s over the last 12 months.

IMUX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as FOLD (100) in the Biotechnology industry. This means that IMUX’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDIMUX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
68%
Bullish Trend 24 days ago
86%
Declines
ODDS (%)
Bearish Trend 16 days ago
78%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLPTX9.73N/A
N/A
Invesco SteelPath MLP Select 40 Y
MECIX54.08N/A
N/A
AMG GW&K International Small Cap I
BIRDX8.43N/A
N/A
iShares Developed Real Estate Idx Instl
BEMRX10.27N/A
N/A
Brandes Emerging Markets Value R6
RTMTX88.85N/A
N/A
Russell Inv Tax-Managed US Large Cap M

IMUX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with NTLA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
+2.94%
NTLA - IMUX
39%
Loosely correlated
+8.60%
PLRX - IMUX
36%
Loosely correlated
+2.56%
PROK - IMUX
35%
Loosely correlated
+2.39%
ERAS - IMUX
35%
Loosely correlated
+6.62%
TPST - IMUX
34%
Loosely correlated
+3.33%
More